|
Der Vollständigkeithalber hier die Pressemitteilung vom Dienstag 05.02. CytomX Therapeutics Announces Senior Management Appointments February 5, 2019 at 8:00 AM EST Leadership Team Further Strengthened with Additions of Nick Galli, J.D., as SVP, Chief Business Officer and Leslie Robbins, J.D. as SVP, Intellectual Property SOUTH SAN FRANCISCO, Calif., Feb. 05, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody\u2122 therapeutic technology platform, today announced the appointments of Nick Galli, J.D., as senior vice president, chief business officer and Leslie Robbins, J.D., as senior vice president, intellectual property. “The additions Nick and Leslie to our leadership team reflect our ongoing commitment to partnership formation and aggressive protection of our intellectual property as core pillars of our corporate strategy,” said Sean McCarthy, D.Phil., president, chief executive officer and chairman of CytomX. “Nick’s proven track record in transformational business development and Leslie’s broad and deep IP experience across discovery, development and commercial stages of biologic drug development will be great assets as we seek to maximize the utility of our Probody technology for patients.” Nick Galli, J.D. Mr. Galli brings more than 15 years of transactions experience, most of which has been focused in the biotechnology industry. Most recently, Mr. Galli held the position of vice president, business development at Denali Therapeutics where he led the execution of more than twenty collaborations, including strategic partnerships with Sanofi-Genzyme, Takeda, Genentech and F-star. Prior to Denali, Mr. Galli was senior director, transactions at Johnson & Johnson Innovation Center. Prior to this, Mr. Galli held roles of increasing responsibility at Genentech within the business development and transactional law groups. Mr. Galli began his career as a corporate attorney at the law offices of Skadden, Arps, Slate, Meagher & Flom and practiced in the technology transactions group at Wilson Sonsini Goodrich & Rosati. Mr. Galli received his B.A. degree from Princeton University and his J.D. from the Georgetown University Law Center. “CytomX has the potential to change the treatment paradigm in cancer. I am pleased to be joining a company with a strong track record of clinical development execution and look forward to helping build upon their current portfolio of partnerships,” said Mr. Galli. Leslie Robbins, J.D. Ms. Robbins has over 25 years of legal and intellectual property strategic experience within the biotechnology and pharmaceutical industries. Ms. Robbins joins CytomX from Coherus BioSciences where she held the role of vice president, intellectual property and was responsible for, among other things, the execution of legal strategies in support of the biosimilar platform. Prior to this, she held senior intellectual property counsel roles at Onyx Pharmaceuticals (acquired by Amgen) where she provided strategy and advice on intellectual property related matters related to KYPROLIS\u00ae and Elan Pharmaceuticals where she oversaw all intellectual property matters related to TYSABRI\u00ae, the company’s humanized antibody product. Ms. Robbins began her career at Chiron Corporation and later joined the law firm of Burns, Doane, Swecker & Mathis where she prepared and prosecuted U.S. and foreign patent applications in the biotechnology and pharmaceutical fields. Ms. Robbins received her B.A. degree in microbiology and immunology from the University of California, Berkeley and her J.D. from the Illinois Institute of Technology’s Chicago-Kent College of Law. “I am excited to be a part of a pioneering company committed to improving the lives of cancer patients. I look forward to sharing my experiences in assisting companies as they evolve from development to commercial stage as we advance the Probody technology,” said Ms. Robbins. Wenn man das liest, dann scheint Cytomx neue Partnerschaften zu suchen und ihre Patente weiter absichern und verteidigen zu wollen. Ich hoffe allerdings die Absicherung der Patente ist schon zur Genüge passiert. |
|
| aus der Diskussion: | CytomX - ein bahnbrechender Ansatz in der Tumortherapie |
| Autor (Datum des Eintrages): | hinz12 (06.02.19 22:23:08) |
| Beitrag: | 1,018 von 1,459 (ID:59809797) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |